Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of 68GaNOTA-Anti-HER2 VHH1 uptake in brain metastasis of cancer patients
2015-002328-24Phase 2Active
- Sponsor
- UZ Brussel
- Start
- Jul 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of [68Ga]Ga-NOTA-ABSCINT-HER2 in brain metastases (2 arms), sponsored by UZ Brussel. Primary endpoint: Tumor targeting potential in brain metastasis. Started Jul 2015; status: active.
02
Drugs
[68Ga]Ga-NOTA-ABSCINT-HER2
03
Conditions
brain metastases
Beyond the preview
Go deeper on 2015-002328-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002328-24.